Literature DB >> 2835911

Hepatocellular carcinoma: importance of histologic classification as a prognostic factor.

W J Wood1, M Rawlings, H Evans, C N Lim.   

Abstract

The characteristics and clinical courses of 15 patients with fibrolamellar carcinoma have been compared to 62 patients with hepatocellular carcinoma treated over the same time period. Marked differences were found in patient, tumor, and treatment characteristics. Survival rates in these two groups of patients have been compared by univariate analysis of the subsets of those patient, tumor, and treatment characteristics. The longer survival of the group of patients with fibrolamellar carcinoma could not be accounted for by the prevalence or absence of any of these characteristics. Comparison of subsets of patients with documented noncirrhotic livers or those having complete resection of their tumors revealed a significantly prolonged survival in patients with the fibrolamellar variant. The 5 year survival rate of the patients with fibrolamellar carcinoma who had complete tumor resection was 45 percent, with a median survival time of 50 months. The 5 year survival of patients with hepatocellular carcinoma who had complete tumor resection was 0 percent, with a median survival time of 22 months.

Entities:  

Mesh:

Year:  1988        PMID: 2835911     DOI: 10.1016/s0002-9610(88)80139-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

1.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.

Authors:  A D Pinna; S Iwatsuki; R G Lee; S Todo; J R Madariaga; J W Marsh; A Casavilla; I Dvorchik; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

3.  Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma.

Authors:  Chaur-Shine Wang; Chih-Lin Lin; Hsi-Chang Lee; Kuan-Yang Chen; Ming-Feng Chiang; Hung-Sheng Chen; Tsung-Jung Lin; Li-Ying Liao
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

Review 4.  Therapeutic modalities and prognostic factors for primary and secondary liver tumors.

Authors:  T Lehnert; G Otto; C Herfarth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

5.  Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Basile Njei; Venkata Rajesh Konjeti; Ivo Ditah
Journal:  Gastrointest Cancer Res       Date:  2014-03

6.  Fibrolamellar hepatocellular carcinoma in mexican patients.

Authors:  Julian Arista-Nasr; Lisa Gutierrez-Villalobos; Juan Nuncio; Hector Maldonaldo; Leticia Bornstein-Quevedo
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

7.  Late supra-diaphragmatic lymph node recurrence following resection of a fibrolamellar hepatocarcinoma: an unusual case.

Authors:  Basile Tsilividis; Emmanuel Huet; Jean Lubrano; Laurence Lacaze; Jean Pierre Lestrat; Arnaud François; Ghassan Riachi; Michel Scotté
Journal:  Surg Radiol Anat       Date:  2009-09-24       Impact factor: 1.246

Review 8.  Liver transplantation for hepatocellular carcinoma: clinical results and future aspects.

Authors:  R Pichlmayr; A Weimann; G Steinhoff; B Ringe
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

Authors:  B Ringe; R Pichlmayr; C Wittekind; G Tusch
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

Review 10.  Current treatment modalities for hepatocellular carcinoma.

Authors:  D G Farmer; M H Rosove; A Shaked; R W Busuttil
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.